Glitazone Treatment and Incidence of Parkinson’s Disease among People with Diabetes: A Retrospective Cohort Study

BACKGROUND: Recent in vitro and animal experiments suggest that peroxisome proliferation-activated receptor gamma (PPARɣ) agonist medications, such as antidiabetic glitazone (GTZ) drugs, are neuroprotective in models of Parkinson’s disease (PD). These findings have not been tested in humans. We hypo...

Descripción completa

Detalles Bibliográficos
Autores principales: Brauer, Ruth, Bhaskaran, Krishnan, Chaturvedi, Nishi, Dexter, David T., Smeeth, Liam, Douglas, Ian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511413/
https://www.ncbi.nlm.nih.gov/pubmed/26196151
http://dx.doi.org/10.1371/journal.pmed.1001854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511413/
https://www.ncbi.nlm.nih.gov/pubmed/26196151
http://dx.doi.org/10.1371/journal.pmed.1001854

Ejemplares similares